Ads
related to: treatment of thrombocytopenia in cirrhosis patients- Can You Diagnose HRS?
Play Our Game
To Test Your Knowledge.
- Address Treatment Urgency
See Diagnostic Criteria
To Identify HRS-AKI Earlier.
- Download Resources
Discover & Download HRS
Resources On The Website.
- Learn More About HRS-AKI
Discover The AASLD & ACG
Recommended Therapy For HRS.
- Request A Rep
Get In Touch For More Info
Or Request To Speak To A Rep.
- View Safety & Efficacy
Learn About The Primary End Point
And Data For The Treatment Of HRS.
- Can You Diagnose HRS?
wiserlifestyles.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. [3] [4] Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. [6]
Lusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. [1]
Acute liver failure is the appearance of severe complications rapidly after the first signs (such as jaundice) of liver disease, and indicates that the liver has sustained severe damage (loss of function of 80–90% of liver cells).
Treatment is guided by the severity and specific cause of the disease. Treatment focuses on eliminating the underlying problem, whether that means discontinuing drugs suspected to cause it or treating underlying sepsis. Diagnosis and treatment of serious thrombocytopenia is usually directed by a hematologist.
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, chronic liver failure or chronic hepatic failure and end-stage liver disease, is an acute condition of the liver in which the normal functioning tissue, or parenchyma, is replaced with scar tissue and regenerative nodules as a result of chronic liver disease.
Treatment is aimed at opening the blocked veins to minimize complications; the duration of clot (acute versus chronic) affects treatment. Unless there are underlying reasons why it would be harmful, anticoagulation ( low molecular weight heparin , followed by warfarin ) is often initiated and maintained in patients who do not have cirrhosis.
Ad
related to: treatment of thrombocytopenia in cirrhosis patients